Human fetal brain self-organizes into long-term expanding organoids.

CRISPR-Cas9 ECM brain cancer brain development human fetal brain morphogens organoids regional identity tissue culture tumor modeling

Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
04 Jan 2024
Historique:
received: 13 12 2022
revised: 27 09 2023
accepted: 05 12 2023
medline: 10 1 2024
pubmed: 10 1 2024
entrez: 9 1 2024
Statut: aheadofprint

Résumé

Human brain development involves an orchestrated, massive neural progenitor expansion while a multi-cellular tissue architecture is established. Continuously expanding organoids can be grown directly from multiple somatic tissues, yet to date, brain organoids can solely be established from pluripotent stem cells. Here, we show that healthy human fetal brain in vitro self-organizes into organoids (FeBOs), phenocopying aspects of in vivo cellular heterogeneity and complex organization. FeBOs can be expanded over long time periods. FeBO growth requires maintenance of tissue integrity, which ensures production of a tissue-like extracellular matrix (ECM) niche, ultimately endowing FeBO expansion. FeBO lines derived from different areas of the central nervous system (CNS), including dorsal and ventral forebrain, preserve their regional identity and allow to probe aspects of positional identity. Using CRISPR-Cas9, we showcase the generation of syngeneic mutant FeBO lines for the study of brain cancer. Taken together, FeBOs constitute a complementary CNS organoid platform.

Identifiants

pubmed: 38194967
pii: S0092-8674(23)01344-2
doi: 10.1016/j.cell.2023.12.012
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests D.H., B.A., and H.C. are inventors on a patent related to this work. The full disclosure of H.C. is given at https://www.uu.nl/staff/JCClevers/.

Auteurs

Delilah Hendriks (D)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands. Electronic address: d.hendriks@hubrecht.eu.

Anna Pagliaro (A)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Francesco Andreatta (F)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Ziliang Ma (Z)

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(∗)STAR), Immunos, Singapore 138648, Singapore; Department of Pharmacy, National University of Singapore, Singapore 117543, Singapore.

Joey van Giessen (J)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Simone Massalini (S)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Carmen López-Iglesias (C)

The Maastricht Multimodal Molecular Imaging Institute, Maastricht University, Maastricht, the Netherlands.

Gijs J F van Son (GJF)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands.

Jeff DeMartino (J)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

J Mirjam A Damen (JMA)

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.

Iris Zoutendijk (I)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Nadzeya Staliarova (N)

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.

Annelien L Bredenoord (AL)

Erasmus School of Philosophy, Erasmus University Rotterdam, Rotterdam, the Netherlands.

Frank C P Holstege (FCP)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Center for Molecular Medicine, University Medical Center Utrecht and Utrecht University, Utrecht, the Netherlands.

Peter J Peters (PJ)

The Maastricht Multimodal Molecular Imaging Institute, Maastricht University, Maastricht, the Netherlands.

Thanasis Margaritis (T)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Susana Chuva de Sousa Lopes (S)

Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, the Netherlands.

Wei Wu (W)

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(∗)STAR), Immunos, Singapore 138648, Singapore; Department of Pharmacy, National University of Singapore, Singapore 117543, Singapore.

Hans Clevers (H)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands. Electronic address: h.clevers@hubrecht.eu.

Benedetta Artegiani (B)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Electronic address: b.a.artegiani@prinsesmaximacentrum.nl.

Classifications MeSH